A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Completed · Phase 2

Conditions studied: Conjunctivitis, Allergic

In brief

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.

Key facts

Study ID
NCT03012165
Run by
Aldeyra Therapeutics, Inc.
People needed
154
Starts
2016-12-01
Expected to finish
2017-05-01
Last updated by the study team
2023-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.